We are live on ! Find out more
EPZM

Epizyme, Inc
EPZM

Delisted

EPZM was delisted on the 11th of August, 2022.

Back to rankings

82 hedge funds and large institutions have $447M invested in Epizyme, Inc in 2014 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 26 increasing their positions, 25 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,239% more call options, than puts

Call options by funds: $241K | Put options by funds: $18K

4% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 25

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

13% less funds holding

Funds holding: 94 → 82 (-12)

30% less capital invested

Capital invested by funds: $639M → $447M (-$191M)

36% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 25

Holders
82
Holders Change
-12
Holders Change %
-12.77%
% of All Funds
2.19%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
16
Increased
26
Reduced
25
Closed
25
Calls
$241K
Puts
$18K
Net Calls
+$223K
Net Calls Change
-$511K

Top Buyers

Rank Fund Capital Flow
1
Primecap Management
Primecap Management
California
+$62.9M
2
Norges Bank
Norges Bank
Norway
+$7.74M
3
EA
Emerald Advisers
Pennsylvania
+$5.28M
4
Millennium Management
Millennium Management
New York
+$4.34M
5
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
+$4.15M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$15.9M
2
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$15.3M
3
State Street
State Street
Massachusetts
-$12.2M
4
Capital World Investors
Capital World Investors
California
-$10.4M
5
JP Morgan Chase
JP Morgan Chase
New York
-$10.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
NI
26
Numeric Investors
Massachusetts
$1.11M -$2.03M -86,904 -60%
JP Morgan Chase
27
JP Morgan Chase
New York
$1.07M -$10.4M -444,227 -89%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$1.07M -$83.2K -3,561 -6%
ARTA
29
A.R.T. Advisors
New York
$1.06M +$948K +40,591 +256%
Morgan Stanley
30
Morgan Stanley
New York
$1.02M -$106K -4,556 -8%
CS
31
Credit Suisse
Switzerland
$978K +$136K +5,803 +13%
CCMH
32
Cornerstone Capital Management Holdings
New York
$977K +$640K +27,400 +112%
Citadel Advisors
33
Citadel Advisors
Florida
$962K -$4.13M -176,600 -78%
TI
34
Trexquant Investment
Connecticut
$879K +$1.09M +46,613 New
TCIM
35
TIAA CREF Investment Management
New York
$873K -$44.7K -1,912 -4%
BA
36
BlackRock Advisors
Delaware
$736K +$759K +32,504 +499%
Deutsche Bank
37
Deutsche Bank
Germany
$690K +$79.8K +3,418 +10%
Charles Schwab
38
Charles Schwab
California
$690K +$195K +8,328 +30%
BIM
39
BlackRock Investment Management
Delaware
$661K -$8.25K -353 -1%
Connor, Clark & Lunn Investment Management (CC&L)
40
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$630K +$780K +33,400 New
TC
41
TFS Capital
Pennsylvania
$625K +$409K +17,503 +112%
OPPM
42
Opus Point Partners Management
New York
$535K +$662K +28,339 New
Goldman Sachs
43
Goldman Sachs
New York
$521K +$359K +15,373 +125%
ProShare Advisors
44
ProShare Advisors
Maryland
$479K +$69.8K +2,987 +13%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$448K -$787K -33,676 -59%
Massachusetts Financial Services
46
Massachusetts Financial Services
Massachusetts
$379K +$470K +20,103 New
Macquarie Group
47
Macquarie Group
Australia
$377K – – –
TA
48
Teachers Advisors
New York
$343K – – –
HTHT
49
Hemenway Trust Hemenway Trust
New Hampshire
$340K – – –
DekaBank Deutsche Girozentrale
50
DekaBank Deutsche Girozentrale
Germany
$321K -$39.7K -1,700 -9%
1
2
3 4 5

EPZM Hedge Fund Activity: Q4 2014 in Review

82 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q4 2014, worth a combined $447M — down 30% from $639M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of EPZM and 16 opened new positions — a net loss of 9 holders — while 25 trimmed existing stakes and 26 added.

The largest buyer was Primecap Management, adding an estimated $62.9M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $15.9M sold.

  • 82 institutional investors held Epizyme, Inc (EPZM) as of Q4 2014, down from 94 in Q3 2014.
  • Funds reported $447M of Epizyme, Inc stock for Q4 2014, down 30% quarter-over-quarter.
  • 16 funds opened new Epizyme, Inc positions in Q4 2014 and 25 closed out, a net change of -9 holders.
  • The largest Epizyme, Inc buyer in Q4 2014 was Primecap Management, an estimated $62.9M added.
  • The largest Epizyme, Inc seller in Q4 2014 was T. Rowe Price Associates, an estimated $15.9M sold.

Based on aggregated 13F filings for Q4 2014.